IN2012DN00572A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00572A
IN2012DN00572A IN572DEN2012A IN2012DN00572A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A IN 572DEN2012 A IN572DEN2012 A IN 572DEN2012A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A
Authority
IN
India
Prior art keywords
compositions
treating
methods
provides
present
Prior art date
Application number
Other languages
English (en)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Irm Llc filed Critical Scripps Research Inst
Publication of IN2012DN00572A publication Critical patent/IN2012DN00572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN572DEN2012 2009-07-14 2010-07-13 IN2012DN00572A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
PCT/US2010/041850 WO2011008773A2 (fr) 2009-07-14 2010-07-13 Différentiation de cellules souches mésenchymateuses

Publications (1)

Publication Number Publication Date
IN2012DN00572A true IN2012DN00572A (fr) 2015-06-12

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572DEN2012 IN2012DN00572A (fr) 2009-07-14 2010-07-13

Country Status (31)

Country Link
US (4) US9139633B2 (fr)
EP (1) EP2453921B1 (fr)
JP (1) JP5602850B2 (fr)
KR (3) KR20160015403A (fr)
CN (2) CN102625830B (fr)
AU (1) AU2010273570B2 (fr)
BR (1) BR112012000914B8 (fr)
CA (1) CA2767826C (fr)
CL (1) CL2012000091A1 (fr)
CO (1) CO6491059A2 (fr)
CR (1) CR20120024A (fr)
CU (1) CU24042B1 (fr)
EA (1) EA023073B1 (fr)
EC (1) ECSP12011604A (fr)
ES (1) ES2541217T3 (fr)
GT (1) GT201200011A (fr)
HK (1) HK1164169A1 (fr)
IL (2) IL217383A (fr)
IN (1) IN2012DN00572A (fr)
MA (1) MA33423B1 (fr)
MX (1) MX2012000707A (fr)
MY (1) MY160951A (fr)
NZ (1) NZ597306A (fr)
PE (2) PE20120570A1 (fr)
PL (1) PL2453921T3 (fr)
PT (1) PT2453921E (fr)
SG (1) SG177318A1 (fr)
TN (1) TN2011000655A1 (fr)
UA (1) UA104031C2 (fr)
WO (1) WO2011008773A2 (fr)
ZA (1) ZA201200078B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33423B1 (fr) * 2009-07-14 2012-07-03 Scripps Research Inst Différentiation de cellules souches mésenchymateuses
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN109996082B (zh) 2011-11-08 2022-01-25 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2014151953A1 (fr) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Composés et procédés pour l'induction de la chondrogenèse
KR102375396B1 (ko) 2014-05-13 2022-03-18 노파르티스 아게 연골형성을 유도하기 위한 화합물 및 조성물
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
IL266361B2 (en) * 2016-11-14 2024-02-01 Novartis Ag Methods and preparations for the treatment of cartilage damage and arthritis
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
ES2965684T3 (es) * 2018-12-06 2024-04-16 Novartis Ag Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
JP7471291B2 (ja) 2018-12-06 2024-04-19 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (fr) 1998-04-27 1999-11-04 Zymogenetics, Inc. Nouveaux facteurs et materiels de croissance polypeptidiques et leurs procedes de production
CA2332109A1 (fr) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 proteines humaines secretees
WO1999067382A2 (fr) * 1998-06-24 1999-12-29 Compugen Ltd. Sequences d'un facteur de croissance apparente a l'angiopoietine
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
JP2003505350A (ja) 1999-07-20 2003-02-12 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040249141A1 (en) * 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
EP1326980B1 (fr) 2000-10-16 2008-03-19 Genentech, Inc. Techniques de traitement utilisant des polypeptides wisp
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN1615440A (zh) * 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
KR100974843B1 (ko) * 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
WO2004081174A2 (fr) * 2003-03-10 2004-09-23 Japan Science And Technology Agency Marqueur pour detecter une cellule souche mesenchymateuse et procede pour distinguer une cellule souche mesenchymateuse au moyen d'un marqueur
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
EP1771196B1 (fr) * 2004-06-21 2012-03-28 The Cleveland Clinic Foundation Ligands ccr pour domiciliation de cellules souches
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2006127809A2 (fr) 2005-05-24 2006-11-30 Whitehead Institute For Biomedical Research Procedes pour le developpement et l'analyse de cellules souches hematopoietiques de culture
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (fr) * 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Développement ex vivo de cellules souches hématopoïétiques humaines
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
MA33423B1 (fr) * 2009-07-14 2012-07-03 Scripps Research Inst Différentiation de cellules souches mésenchymateuses
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
CN102625830B (zh) 2016-03-02
WO2011008773A3 (fr) 2011-08-25
US20160213748A1 (en) 2016-07-28
CR20120024A (es) 2012-06-11
ZA201200078B (en) 2013-01-30
PE20120570A1 (es) 2012-05-19
AU2010273570B2 (en) 2014-07-03
BR112012000914B1 (pt) 2021-04-06
GT201200011A (es) 2013-12-10
MY160951A (en) 2017-03-31
US10064918B2 (en) 2018-09-04
CA2767826C (fr) 2015-11-24
IL247310B (en) 2018-04-30
EP2453921B1 (fr) 2015-05-27
CU24042B1 (es) 2014-11-27
TN2011000655A1 (en) 2013-05-24
IL217383A0 (en) 2012-02-29
US11241482B2 (en) 2022-02-08
EP2453921A2 (fr) 2012-05-23
PE20160507A1 (es) 2016-05-20
CL2012000091A1 (es) 2012-10-26
EP2453921A4 (fr) 2012-12-19
MA33423B1 (fr) 2012-07-03
AU2010273570A1 (en) 2012-02-02
WO2011008773A2 (fr) 2011-01-20
KR20180000337A (ko) 2018-01-02
US20190000922A1 (en) 2019-01-03
HK1164169A1 (en) 2012-09-21
EA023073B1 (ru) 2016-04-29
JP2012533549A (ja) 2012-12-27
CA2767826A1 (fr) 2011-01-20
KR20120029472A (ko) 2012-03-26
CN102625830A (zh) 2012-08-01
EA201200118A1 (ru) 2012-09-28
US20200108122A1 (en) 2020-04-09
US20120177644A1 (en) 2012-07-12
BR112012000914B8 (pt) 2021-05-25
NZ597306A (en) 2014-03-28
CU20120007A7 (es) 2013-02-26
BR112012000914A2 (pt) 2017-08-08
IL217383A (en) 2016-08-31
US10555990B2 (en) 2020-02-11
MX2012000707A (es) 2012-03-21
ES2541217T3 (es) 2015-07-16
KR20160015403A (ko) 2016-02-12
PL2453921T3 (pl) 2015-11-30
PT2453921E (pt) 2015-09-25
CN105601728A (zh) 2016-05-25
UA104031C2 (uk) 2013-12-25
SG177318A1 (en) 2012-03-29
JP5602850B2 (ja) 2014-10-08
CO6491059A2 (es) 2012-07-31
KR101590834B1 (ko) 2016-02-12
BR112012000914A8 (pt) 2017-12-19
CN105601728B (zh) 2020-01-10
ECSP12011604A (es) 2012-06-29
US9139633B2 (en) 2015-09-22

Similar Documents

Publication Publication Date Title
IN2012DN00572A (fr)
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2009008222A (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
EP2569330A4 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d'utilisation
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
IN2012DN03883A (fr)
MY172372A (en) Compositions and methods for lowering triglycerides
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
IN2012DN02624A (fr)
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
EP4023243A3 (fr) Compositions et procédés pour le traitement de la maladie c liaque
WO2012017321A3 (fr) Traitement de la dyslipidémie
WO2010037095A3 (fr) Agents et procédés pour le traitement du cancer
MX2010002950A (es) Metodos y composiciones para deteccion de ehrlichia chaffeensis (vlpt).
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MY165088A (en) Pharmaceutical compositions comprising alisporivir